Dr Alok | Lorlatinib in Management of ALK rearranged NSCLC

preview_player
Показать описание
Cancer Research And Statistic Foundation organized a webinar "Management of Breast & Lung Cancer" with the support of "Institute of Pulmonology Medical Research & Development" & "Sunrise Oncology Centre".

Date: 2 April 2022
Time: 05:00 pm to 09:00 pm

Follow us:

Event Managed By:
Horizon Conference Management

#crsf #BreastandlungCancer #Cancer #Oncology #OncoCare
  1. CRSF - Cancer Research and Statistic Foundation
  2. crsf
  3. cancer research
  4. oncology
  5. oncologist
  6. crsf india
Рекомендации по теме
Dr Alok | 0:24:02

Dr Alok | Lorlatinib in Management of ALK rearranged NSCLC

Disease Progression on 0:03:55

Disease Progression on Lorlatinib or Osimertinib - 2022 Program: Targeted Therapies Forum

Dr N K 0:05:24

Dr N K Warrier | Phase II study of Lorlatinib in Patients with Anaplastic Lymphoma Kinase

Dr Alastair Greystoke 0:41:24

Dr Alastair Greystoke debates with Dr Tom Newsom-Davis “Lorlatinib – first or last?”

2020 TTF ALK 0:01:43

2020 TTF ALK SESSION QA PANEL Reducing Dosage on Lorlatinib vs Switching to a Different Agent

Dr Anmol Dongre 0:18:29

Dr Anmol Dongre | Lorlatinib as front line option in ALK+ mNSCLC

Lorlatinib is Already 0:01:41

Lorlatinib is Already Failing

45th ICON Live 0:18:06

45th ICON Live discussion on Lorlatinib as Front-line treatment in ALK+ mNSCLC

Available Treatment Options 0:03:08

Available Treatment Options for Relapsed ALK-Rearranged NSCLC

Dr Mridul Malhotra 0:08:42

Dr Mridul Malhotra | Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients

GRACECast - LCVL- 0:05:42

GRACECast - LCVL- What are the options after a patient with an ALK-positive advanced NSCLC develops

Future work on 0:01:30

Future work on rimegepant for migraines

Onset of migraine 0:02:02

Onset of migraine preventive effects with rimegepant in a Phase II/III trial

Dr. Ramalingam on 0:02:22

Dr. Ramalingam on Plasma EGFR Mutations as a Predictor of Response in NSCLC